Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Japan Sales of “Huge Seller” Quartet Each Break 110 Billion Yen in 2015: IMS
Four drugs that will be hit by a new re-pricing rule for fast-growing blockbusters all rang up Japan sales of over 110 billion yen in 2015 on an NHI price basis, according to data released by IMS Health on February…
To read the full story
Related Article
- Gilead, Bristol Take Quantum Leaps in 2015, Lilly Logs Double-Digit Growth: IMS
February 10, 2016
- Sovaldi Best-Selling Drug in July-September after May Launch: IMS
November 11, 2015
- Antithrombotic Agent Sales Up 7.4% in 2014 on Buoyant Plavix, Xarelto: IMS
February 13, 2015
- Japan Pharma Market Grows 1.4% in 2014, Plavix Retains Crown in Sales Ranking: IMS
February 13, 2015
BUSINESS
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Pfizer Seeks Pediatric Expansion for Hympavzi in Japan
July 31, 2026
- Nippon Shinyaku Exercises Option for AB2 Bio’s Tadekinig Alfa in US
July 31, 2026
- Alfresa Takes Stake in Ember to Bolster Pharma Cold Chain in Japan
July 31, 2026
- Sanwa Kagaku Says Kumamoto Plant Remains Shut, Drug Supplies Stable
July 31, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…